Recent Advances in Cirrhotic Cardiomyopathy

Digestive Diseases and Sciences

Volumn 60, Issue 5, 2015, Pages 1141-1151

  Karagiannakis, Dimitrios S ^a   Papatheodoridis, George ^a   Vlachogiannakos, Jiannis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cardiomyopathy; Cirrhosis; Hyperdynamic circulation; Portal hypertension

Indexed keywords

CARDIOVASCULAR AGENT;

ACTION POTENTIAL; ANIMAL; CARDIOMYOPATHIES; COMPLICATION; HEART MUSCLE; HEART MUSCLE CONDUCTION SYSTEM; HEART VENTRICLE; HEART VENTRICLE FUNCTION; HEMODYNAMICS; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; METABOLISM; MORTALITY; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

ACTION POTENTIALS; ANIMALS; CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; HEART CONDUCTION SYSTEM; HEART VENTRICLES; HEMODYNAMICS; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MYOCARDIUM; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; VENTRICULAR FUNCTION;

EID: 84937965235     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3432-8     Document Type: Review

References (107)

1. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rode’s J. Peripheral artery vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology. 1988;5:1151–1157.
2. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule. Hepatology. 2006;43:S121–S131.157.
3. Salermo F, Cazzaniga M, Gobbo G. Pharmacological treatment of hepatorenal syndrome: a note of optimism. J Hepatol. 2007;47:729–731.
4. Moller S, Henriksen JH. The systemic circulation in cirrhosis. In: Gines P, Arroyo V, Rodes J, Schrier RW, eds. Ascites and renal dysfunction in liver disease. 2nd ed. Malden: Blackwell; 2005:139–155.
5. Ruiz-del-Arbol L, Monescillo A, Arocena C, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology. 2005;42:439–447.
6. Moller S, Henriksen JH. Cirrhotic cardiomyopathy. J Hepatol. 2010;53:179–190.
7. Alqahtani SA, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Semin Liver Dis. 2008;28:59–69.
8. Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol. 2006;44:994–1002.
9. Bernardi M, Calandra S, Colantoni A, et al. Q-T interval prolongation in cirrhosis: prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology. 1998;27:28–34.
10. Rabie RN, Cazzaniga M, Salermo F, Wong F. The use of E/A ratio as a predictor of outcome in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. Am J Gastroenterol. 2009;104:2458–2466.
11. Trevisani F, Sica G, Mainqua P, et al. Autonomic dysfunction and hyperdynamic circulation in cirrhosis with ascites. Hepatology. 1999;30:1387–1392.
12. Dumcke CW, Moller S. Autonomic dysfunction in cirrhosis and portal hypertension. Scand J Clin Lab Invest. 2008;68:437–447.
13. Lee SS, Marty J, Mantz J, Samain E, Braillon A, Lebrec D. Desensitization of myocardial beta-adrenergic receptors in cirrhotic rats. Hepatology. 1990;12:481–485.
14. Hausdorff WP, Caron MG, Lefkowitz RJ. Turning of the signal: desensitization of β-adrenergic receptor function. FASEB J. 1990;4:2881–2889.
15. Ma Z, Miyamoto A, Lee SS. Role of altered beta-adrenoceptor signal transduction in the pathogenesis of cirrhotic cardiomyopathy in rats. Gastroenterology. 1996;110:1191–1198.
16. Ma Z, Lee SS, Meddings JB. Effects of altered cardiac membrane fluidity on beta-adrenergic receptor signalling in rats with cirrhotic cardiomyopathy. J Hepatol. 1997;26:904–912.
17. Ma Z, Meddings JB, Lee SS. Membrane physical properties determine cardiac b-adrenergic receptor function in cirrhotic rats. Am J Physiol. 1994;267:G87–G93.
18. Ortiz MC, Fortepiani LA, Martinez C, Atucha NM, Garcia-Estan J. Vascular hyporesponsiveness in aortic rings from cirrhotic rats: role of nitric oxide and endothelium. Clin Sci (Lond). 1996;91:733–738.
19. Ebrahimi F, Tavacoli S, Hairasouliha AR, et al. Involvement of endogenous opioid peptides and nitric oxide in the blunted chronotropic and inotropic responses to beta-adrenergic stimulation in cirrhotic rats. Fundam Clin Pharmacol. 2006;20:461–471.
20. Hare JM, Colucci WS. Role of nitric oxide in the regulation of myocardial function. Prog Cardiovasc Dis. 1995;38:155–166.
21. Kelly RA, Balligand JL, Smith TW. Nitric oxide and cardiac function. Circ Res. 1996;79:363–380.
22. Liu H, Ma Z, Lee SS. Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Gastroenterology. 2000;118:937–944.
23. Yang YY, Liu H, Nam SW, Kunos G, Lee SS. Mechanisms of TNFα-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFα and endocannabinoids. J Hepatol. 2010;53:298–306.
24. Gaskari SE, Liu H, Moezi L, et al. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol. 2005;146:315–323.
25. 2+ channel current. Am J Physiol. 1999;276:H2085–H2093.
26. Howlett AC, Bidaut-Russell M, Devane WA, et al. The cannabinoid receptor: biochemical, anatomical and behavioral characterization. Trends Neurosci. 1990;13:420–423.
27. Batkai S, Mukhopadhyay P, Harvey-White J, et al. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol. 2007;293:H1689–H1695.
28. Varga K, Wagner JA, Bridgen DT, Kunos G. Platelet and macrophages derived endogenous cannabinoid are involved in endotoxine induced hypotension. FASEB J. 1998;12:1035–1044.
29. Maccarrone M, De Petrocellis L, Bari M, et al. Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch Biochem Biophys. 2001;393:321–328.
30. Liu J, Batkai S, Pacher P, et al. Lipopolysaccharide induces anandamide synthesis in macrophages via CD14/MARK/phosphoinositide 3-kinase/NK-kappaB independently of platelet-activating factor. J Biol Chem. 2003;278:45034–45039.
31. Maccarrone M, Bari M, Battista N, Finazzi-Agro A. Endocannabinoid degradation, endotoxic shock and inflammation. Curr Drug Targets Inflamm Allergy. 2002;1:53–63.
32. Rozenberg S, Besse S, Brisson H, et al. Endotoxin-induced myocardial dysfunction in senescent rats. Crit Care. 2006;10:R124.
33. Karagiannakis DS, Vlachogiannakos J, Anastasiadis G, Vafiadis-Zouboulis I, Ladas SD. Frequency and severity of cirrhotic cardiomyopathy and its possible relationship with bacterial endotoxaemia. Dig Dis Sci. 2013;58:3029–3036.
34. Jacob G, Nassar N, Hayam G, et al. Cardiac function and responsiveness to β-adrenoceptor agonists in rats with obstructive jaundice. Am J Physiol. 1993;265:G314–G320.
35. Zavecz JH, Battarbee HD. The role of lipophilic bile acids in the development of cirrhotic cardiomyopathy. Cardiovasc Toxicil. 2010;10:117–129.
36. Glenn TK, Honar H, Liu H, ter Keurs HEDJ, Lee SS. Role of cardiac myofilament proteins titin and collagen in the pathogenesis of diastolic dysfunction in cirrhotic rats. J Hepatol. 2011;55:1249–1255.
37. Ward CA, Ma Z, Lee SS, Giles WR. Potassium currents in atrial and ventricular myocytes from a rat model of cirrhosis. Am J Physiol. 1997;273:G537–G544.
38. Ward CA, Liu H, Lee SS. Altered cellular calcium regulatory systems in a rat model of cirrhotic cardiomyopathy. Gastroenterology. 2001;121:1209–1218.
39. Moller S, Henriksen JH. Cardiovascular dysfunction in cirrhosis. Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand J Gastroenterol. 2001;36:785–794.
40. Pozzi M, Redaelli E, Ratti L, et al. Time-course of diastolic dysfunction in different stages of chronic HCV related liver diseases. Minerva Gastroenterol Dietol. 2005;51:179–186.
41. Torregrosa M, Aguade S, Dos L, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol. 2005;42:68–74.
42. Finucci G, Desideri A, Sacerdoti D, et al. Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol. 1996;31:279–284.
43. Pozzi M, Carugo S, Boari G, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology. 1997;26:1131–1137.
44. Wong F, Villamil A, Merli M, et al. Prevalence of diastolic dysfunction in cirrhosis, and its clinical significance. Hepatology. 2011;54:475A–476A.
45. Ho CY, Solomon SD. Clinician’s guide to tissue Doppler imaging. Circulation. 2006;113:e396–e398.
46. Kazankov K, Holland-Fischer P, Andersen NH, et al. Resting myocardial dysfunction in cirrhosis quantified by tissue Doppler imaging. Liver Int. 2011;31:534–540.
47. Andersen UB, Moller S, Bendtsen F, Henriksen JH. Cardiac output determined by echocardiography in patients with cirrhosis: comparison with the indicator dilution technique. Eur J Gastroenterol Hepatol. 2003;15:503–507.
48. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22:107–133.
49. Sampaio F, Pimenta J, Bettencourt N, et al. Systolic and diastolic dysfunction in cirrhosis: a tissue-Doppler and speckle tracking echocardiography study. Liver int. 2013;33:1158–1165.
50. Ruiz-del Arbol L, Achecar L, Serradilla R, et al. Diastolic dysfunction is a predictor of poor outcomes in patients with cirrhosis, portal hypertension and a normal creatinine. Hepatology. 2013;58:1732–1741.
51. Merli M, Valeriano V, Funaro S, et al. Modifications of cardiac function in cirrhotic patients treated with transjugular intrahepatic portosystemic shunt (TIPS). Am J Gastroenterol. 2002;97:142–148.
52. Kovacs A, Schepke M, Heller J, Schild HH, Flacke S. Short-term effects of transjugular intrahepatic shunt on cardiac function assessed by cardiac MRI: preliminary results. Cardiovasc Intervent Radiol. 2010;33:290–296.
53. Cazzaniga M, Salerno F, Pagnozzi G, et al. Diastolic dysfunction is associated with poor survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt. Gut. 2007;56:869–875.
54. Ripoll C, Catalina MV, Yotti R, et al. Cardiac dysfunction during liver transplantation: incidence and preoperative predictors. Transplantation. 2008;85:1766–1772.
55. Nazar A, Guevara M, Sitges M, et al. Left ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction. J Hepatol. 2013;58:51–57.
56. Alexopoulou A, Papatheodoridis G, Pouriki S, et al. Diastolic myocardial dysfunction does not affect survival in patients with cirrhosis. Transpl Int. 2012;25:1174–1181.
57. Merli M, Calicchia A, Ruffa A, et al. Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease. Eur J Intern Med. 2013;24:172–176.
58. Sampaio F, Pimenta J, Bettencourt N, et al. Systolic dysfunction and diastolic dysfunction do not influence medium-term prognosis in patients with cirrhosis. Eur J Intern Med. 2014;25:241–246.
59. Karagiannakis D, Vlachogiannakos J, Anastasiadis G, Vafiadis-Zoumboulis I, Ladas SD. Diastolic cardiac dysfunction is a predictor of dismal prognosis in patients with liver cirrhosis. Hepatol Int. 2014;8:588–594.
60. Grose RD, Nolan J, Dilon JF, et al. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol. 1995;22:326–332.
61. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut. 2001;49:268–275.
62. Kim MY, Baik SK, Won CS, et al. Dobutamine stress echocardiography for evaluating cirrhotic cardiomyopathy in liver cirrhosis. Korean J Hepatol. 2010;16:376–382.
63. Krag A, Bendtsen F, Burroughs AK, Moller S. The cardiorenal link in advanced cirrhosis. Med Hypotheses. 2012;79:53–55.
64. Moller S, Hove JD, Dixen U, Bendtsen F. New insights into cirrhotic cardiomyopathy. Int J Cardiol. 2013;167:1101–1108.
65. Krag A, Bendtsen F, Henriksen JH, Moller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut. 2010;59:105–110.
66. Ruiz-Del-Arbol L, Urman J, Fernandez J. et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis Hepatology. 2003;38:1210–1218.
67. Henriksen JH, Goetze JP, Fuglsang S, et al. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut. 2003;52:1511–1517.
68. Pimenta J, Paulo C, Gomes A, Silva S, Rocha-Goncalves F, Bettencourt P. B-type natriuretic peptide is related to cardiac function and prognosis in hospitalized patients with decompensated cirrhosis. Liver Int. 2010;30:1059–1066.
69. Saner FH, Neumann T, Canbay A, et al. High brain-natriuretic peptide level predicts cirrhotic cardiomyopathy in liver transplant patients. Transpl Int. 2011;24:425–432.
70. Bernardi M, Maggioli C, Dibra V, Zaccherini G. QT interval prolongation in liver cirrhosis: innocent bystander or serious threat? Expert Rev Gastroenterol Hepatol. 2012;6:57–66.
71. Trevisani F, Merli M, Savelli F, et al. QT interval in patients with non-cirrhotic portal hypertension and in cirrhotic patients treated with transjugular intrahepatic porto-systemic shunt. J Hepatol. 2003;38:461–467.
72. Ytting H, Henriksen JH, Fuglsang S, Bendtsen F, Moller S. Prolonged Q-Tc interval in mild portal hypertensive cirrhosis. J Hepatol. 2005;43:637–644.
73. Hansen S, Moller S, Bendtsen F, Jensen G, Henriksen JH. Diurnal variation and dispersion in QT interval in cirrhosis: relation to haemodynamic changes. J Hepatol. 2007;47:373–380.
74. Zambruni A, Trevisani F, Di Micoli A, et al. Effect of chronic β-blockage on QT interval in patients with liver cirrhosis. J Hepatol. 2008;48:415–421.
75. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Moller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol. 2002;36:513–520.
76. Reich DL, Wood RK Jr, Emre S, et al. Association of intraoperative hypotension and pulmonary hypertension with adverse outcomes after orthotopic liver transplantation. J Cardiothorac Vasc Anesth. 2003;17:699–702.
77. Glauser FL. Systemic hemodynamic and cardiac function changes in patients undergoing orthotopic liver transplantation. Chest. 1990;98:1210–1215.
78. Navasa M, Feu F, Garcia-Pagan JC, et al. Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology. 1993;17:355–360.
79. Mohamed R, Forsey PR, Davies MK, Neuberger JM. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology. 1996;23:1128–1134.
80. Henderson JM, Mackay GJ, Hooks M, et al. High cardiac output of advanced liver diseases persists after orthotopic liver transplantation. Hepatology. 1992;15:258–262.
81. Piscaglia F, Zironi G, Gaiani S, et al. Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: a long-term prospective study. Hepatology. 1999;30:58–64.
82. Tsochatzis EA, Bosch J, Burroughs AK. New therapeutic paradigm for patients with cirrhosis. Hepatology. 2012;56:1983–1992.
83. Tandon P, Abraldes JG, Berzigotti A, Garcia-Pagan JC, Bosch J. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol. 2010;53:273–282.
84. Wong KY, Wong SY, McSwiggan S, et al. Myocardial fibrosis and QTc are reduced following treatment with spironolactone or amiloride in stroke survivors: a randomised placebo-controlled cross-over trial. Int J Cardiol. 2013;168:5229–5233.
85. Coelho-Filho OR, Shah RV, Neilan TG, et al. Cardiac magnetic resonance assessment of interstitial myocardial fibrosis and cardiomyocyte hypertrophy in hypertensive mice treated with spironolactone. J Am Heart Assoc. 2014;3:e000790.
86. Pozzi M, Grassi G, Ratti L, et al. Cardiac, neuroadrenergic and portal hemodynamic effects of prolonged aldosterone blockage in postviral child A cirrhosis. Am J Gastroenterol. 2005;100:1110–1116.
87. D’Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology. 1995;22:332–354.
88. Andreu V, Perello A, Moitinho E, et al. Total effective vascular compliance in patients with cirrhosis. The role of propranolol. J Hepatol. 2002;36:356–361.
89. Lin HC, Yang YY, Hou MC, Huang YT, Lee FY, Lee SD. Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis. Am J Gastroenterol. 2004;99:1953–1958.
90. Banares R, Moitinho E, Matilla A, et al. Randomised comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology. 2002;36:1367–1373.
91. Dalla Libera L, Ravara B, Gobbo V, et al. Skeletal muscle myofibrillar protein oxidation in heart failure and the protective effect of carvedilol. J Mol Cell Cardiol. 2005;38:803–807.
92. Nanjo S, Yamazaki J, Yoshikawa K, Ishii T, Togane Y. Carvedilol prevents myocardial fibrosis in hamsters. Int Heart J. 2006;47:607–616.
93. Ronsein GE, Guidi DB, Benassi JC, Filho DW, Pedrosa RC. Cytoprotective effects of carvedilol against oxygen free radical generation in rat liver. Redox Rep. 2005;10:131–137.
94. Hobolth L, Bendtsen F, Hansen EF, Moller S. Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: a randomised study. Dig Liver Dis. 2014;46:251–256.
95. Exner DV, Dries DL, Waclawiw MA, Shelton B, Domanski MJ. Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1999;33:916–923.
96. Serste T, Melot C, Francoz C, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 2010;52:1017–1022.
97. Serste T, Francoz C, Durand F, et al. Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol. 2011;55:794–799.
98. Jurgens G, Muller M, Garidel P, et al. Investigation into the interaction of recombinant human serum albumin with Re-lipopolysaccharide and lipid A. J Endotoxin Res. 2002;8:115–126.
99. Dziarski R. Cell-bound albumin is the 70-kDa peptidoglycan-, lipopolysaccharide-, and lipoteichoic acid-binding protein on lymphocytes and macrophages. J Biol Chem. 1994;269:20431–20436.
100. Arroyo V, Garcia-Martinez R, Salvatella X. Human serum albumin, systemic inflammation and cirrhosis. J Hepatol. 2014;61:396–407.
101. Fernandez J, Navasa M, Garcia-Pagan JC, et al. Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol. 2004;41:384–390.
102. Fernandez J, Monteagudo J, Bargallo X, et al. A randomised unblinded pilot study comparing albumina vs. hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology. 2005;42:627–634.
103. Bortoluzzi A, Ceolotto G, Gola E, et al. Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms. Hepatology. 2013;57:266–276.
104. Mancini DM, Katz SD, Lang CC, et al. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation. 2003;107:294–299.
105. Silverberg DS, Wexler D, Sheps D, et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol. 2001;37:1775–1780.
106. Liu L, Liu H, Nam SW, Lee SS. Protective effects of erythropoietin on cirrhotic cardiomyopathy in rats. Dig Liver Dis. 2012;44:1012–1017.
107. Yao J, Zhou CS, Ma X, et al. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation. World J Gastroenterol. 2014;20:14430–14441.